AAAAAA

   
Results: 1-22 |
Results: 22
Methodologic guidelines for the design of high-dose chemotherapy regimens
Authors: Margolin, K Synold, T Longmate, J Doroshow, JH
Citation: K. Margolin et al., Methodologic guidelines for the design of high-dose chemotherapy regimens, BIOL BLOOD, 7(8), 2001, pp. 414-432
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
Authors: Somlo, G Chow, W Hamasaki, V Leong, L Margolin, K Morgan, R Sniecinski, I Frankel, P Reardon, D Longmate, J Raschko, J Shibata, S O'Donnell, M Smith, E Tetef, M Forman, S Yen, Y Molina, A Doroshow, JH
Citation: G. Somlo et al., Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies, BIOL BLOOD, 7(5), 2001, pp. 284-293
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies
Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH
Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576
Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial
Authors: Lara, PN Gandara, DR Longmate, J Gumerlock, PH Martin, DHML Edelman, J Gandour-Edwards, R Mack, PC Israel, V Raschko, J Frankel, P Perez, EA Lenz, HJ Doroshow, JH
Citation: Pn. Lara et al., Activity of high-dose toremifene plus cisplatin in platinum-treated nonsmall-cell lung cancer: a phase II California Cancer Consortium Trial, CANC CHEMOT, 48(1), 2001, pp. 22-28
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy
Authors: Morgan, RJ Synold, T Carr, BI Doroshow, JH Womack, EP Shibata, S Somlo, G Raschko, J Leong, L McNamara, M Chow, W Tetef, M Margolin, K Akman, S Longmate, J
Citation: Rj. Morgan et al., Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy, CANC CHEMOT, 47(4), 2001, pp. 327-332
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
Authors: Morgan, RJ Doroshow, JH Leong, L Schriber, J Shibata, S Forman, S Hamasaki, V Margolin, K Somlo, G Alvarnas, J McNamara, M Longmate, J Raschko, J Chow, W Vasilev, S McGonigle, K Yen, Y
Citation: Rj. Morgan et al., Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer, BONE MAR TR, 28(9), 2001, pp. 859-863
Mice with combined disruption of Gpx1 and Gpx2 genes have colitis
Authors: Esworthy, RS Aranda, R Martin, MG Doroshow, JH Binder, SW Chu, FF
Citation: Rs. Esworthy et al., Mice with combined disruption of Gpx1 and Gpx2 genes have colitis, AM J P-GAST, 281(3), 2001, pp. G848-G855
Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
Authors: Margolin, K Longmate, J Synold, TW Gandara, DR Weber, J Gonzalez, R Johansen, MJ Newman, R Baratta, T Doroshow, JH
Citation: K. Margolin et al., Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium, INV NEW DR, 19(4), 2001, pp. 335-340
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome
Authors: Somlo, G Doroshow, JH Synold, T Longmate, J Reardon, D Chow, W Forman, SJ Leong, LA Margolin, KA Morgan, RJ Raschko, JW Shibata, SI Tetef, ML Yen, Y Kogut, N Schriber, J Alvarnas, J
Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
Authors: List, AF Kopecky, KJ Willman, CL Head, DR Persons, DL Slovak, ML Dorr, R Karanes, C Hynes, HE Doroshow, JH Shurafa, M Appelbaum, FR
Citation: Af. List et al., Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study, BLOOD, 98(12), 2001, pp. 3212-3220
Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin
Authors: Doroshow, JH Synold, TW Somlo, G Akman, SA Gajewski, E
Citation: Jh. Doroshow et al., Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin, BLOOD, 97(9), 2001, pp. 2839-2845
MDR1 bicistronic vectors: analysis of selection stringency, amplified geneexpression, and vector stability in cell lines
Authors: Kane, SE Matsumoto, L Metz, MZ Donohue, CA Lingeman, RG Lin, SW Doroshow, JH
Citation: Se. Kane et al., MDR1 bicistronic vectors: analysis of selection stringency, amplified geneexpression, and vector stability in cell lines, BIOCH PHARM, 62(6), 2001, pp. 693-704
A phase I radioimmunotherapy trial evaluating (90)yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84,66 in patients with metastatic CEA-producing malignancies
Authors: Wong, JYC Chu, DZ Yamauchi, DM Williams, LE Liu, A Wilczynski, S Wu, AM Shively, JE Doroshow, JH Raubitschek, AA
Citation: Jyc. Wong et al., A phase I radioimmunotherapy trial evaluating (90)yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84,66 in patients with metastatic CEA-producing malignancies, CLIN CANC R, 6(10), 2000, pp. 3855-3863
NCCN Practice Guidelines for colorectal cancer
Authors: Engstrom, PF Benson, A Choti, MA Cohen, AM Doroshow, JH Fuchs, C Kiel, K Martin, EW McGinn, C Petrelli, NJ Posey, JA Skibber, JM Venook, A Yeatman, TJ
Citation: Pf. Engstrom et al., NCCN Practice Guidelines for colorectal cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 203-212
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A
Authors: Raschko, JW Synold, TW Chow, W Coluzzi, P Hamasaki, V Leong, LA Margolin, KA Morgan, RJ Shibata, SI Somlo, G Tetef, ML Yen, Y ter Veer, A Doroshow, JH
Citation: Jw. Raschko et al., A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A, CANC CHEMOT, 46(5), 2000, pp. 403-410
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis
Authors: Tetef, ML Margolin, KA Doroshow, JH Akman, S Leong, LA Morgan, RJ Raschko, JW Slatkin, N Somlo, G Longmate, JA Carroll, MI Newman, EM
Citation: Ml. Tetef et al., Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis, CANC CHEMOT, 46(1), 2000, pp. 19-26
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up
Authors: Morgan, RJ Braly, P Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Najera, L Johnson, D Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up, GYNECOL ONC, 77(3), 2000, pp. 433-438
Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
Authors: Wong, JYC Somlo, G Odom-Maryon, T Williams, LE Liu, A Yamauchi, D Wu, AM Yazaki, P Wilczynski, S Shively, JE Forman, S Doroshow, JH Raubitschek, AA
Citation: Jyc. Wong et al., Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer, CLIN CANC R, 5(10), 1999, pp. 3224S-3231S
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial
Authors: Tetef, M Leong, L Ahn, C Akman, S Chow, W Margolin, K Morgan, RJ Raschko, J Shibata, S Somlo, G Doroshow, JH
Citation: M. Tetef et al., Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial, CANCER INV, 17(2), 1999, pp. 114-117
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up
Authors: Morgan, RJ Braly, P Cecchi, G Leong, L Shibata, S Margolin, K Somlo, G McNamara, M Longmate, J Schinke, S Raschko, J Nagasawa, S Kogut, N Parker, P Stein, A Cho, J Smith, E Coluzzi, P Najera, L Johnson, D Womack, E Doroshow, JH
Citation: Rj. Morgan et al., Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up, GYNECOL ONC, 75(3), 1999, pp. 419-426
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma - A Southwest Oncology Group pilot trial
Authors: Leichman, CG Jacobson, JR Modiano, M Daniels, JR Zalupski, MM Doroshow, JH Fletcher, WS Macdonald, JS
Citation: Cg. Leichman et al., Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma - A Southwest Oncology Group pilot trial, CANCER, 86(5), 1999, pp. 775-781
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy
Authors: Somlo, G Sniecinski, I ter Veer, A Longmate, J Knutson, G Vuk-Pavlovic, S Bhatia, R Chow, W Leong, L Morgan, R Margolin, K Raschko, J Shibata, S Tetef, M Yen, Y Forman, S Jones, D Ashby, M Fyfe, G Hellmann, S Doroshow, JH
Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806
Risultati: 1-22 |